Insilico Medicine to present
2021.04.07
NVIDIA GTC 2021
and the end-to-end drug discovery case study at
NVIDIA GTC played a significant role in Insilico Medicine's story
In 2015 Insilco was one of the 12 finalists taking part in the NVIDIA Early Stage Challenge. And while we did not win that time, we got a few NVIDIA K80 GPUs and acquired one of the first NVIDIA DIGITS DevBox platforms. Since then we've taken part in the flagship GTC in San Jose and in multiple regional GTCs including Washington, DC, and Munich. We also became one of the first members of
NVIDIA Inception, an acceleration platform for AI, data science and HPC startups that provides go-to-market support, expertise, and technology.
NVIDIA Inception, an acceleration platform for AI, data science and HPC startups that provides go-to-market support, expertise, and technology.
We are now exploring the applications of the NVIDIA Clara healthcare application framework. Built to support cross-disciplinary workflows, NVIDIA Clara Discovery combines the power of accelerated computing, AI, and machine learning to supercharge the entire drug development process, unlocking the potential to bring life-saving drugs to market faster. Clara Discovery is a collection of frameworks, applications, and AI models enabling GPU-accelerated drug discovery, with support for research in genomics, proteomics, microscopy, virtual screening, computational chemistry, visualization, clinical imaging, and natural language processing (NLP). Browse these tools in NGC, NVIDIA's hub for GPU-optimized software.
We are very happy to be presenting our approach to generative chemistry and the Chemistry42 platform at NVIDIA GTC21 (registration is free) and the application of this platform which enabled the nomination of a preclinical candidate for a novel target for idiopathic pulmonary fibrosis (IPF) in under 18 months.
Drug discovery is a very lengthy and risky process. Here is a video describing the process and our recent novel drug discovery milestone.
We are very happy to be presenting our approach to generative chemistry and the Chemistry42 platform at NVIDIA GTC21 (registration is free) and the application of this platform which enabled the nomination of a preclinical candidate for a novel target for idiopathic pulmonary fibrosis (IPF) in under 18 months.
Drug discovery is a very lengthy and risky process. Here is a video describing the process and our recent novel drug discovery milestone.
Check out our preclinical candidate announcement video and our story of this major milestone in AI-powered drug discovery.
Stay tuned, follow us on social media!
© 2022 Insilico Medicine
HONG KONG
Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong
NEW YORK
345 Park Avenue South,
2nd Floor Suite 006 New York,
NY 10010
2nd Floor Suite 006 New York,
NY 10010
MONTREAL
1250 Rene-Levesque West,
Suite 3710, Montreal, Quebec,
Canada H3B 4W8
Suite 3710, Montreal, Quebec,
Canada H3B 4W8
Subscribe to our news